Ortho Biotech Reiterates Confidence In PROCRIT Safety And Efficacy

Armen Hareyan's picture
Advertisement

PROCRIT

Advertisement

As FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) and Drug Safety and Risk Management Advisory Committee (DSRMAC) meet today to discuss questions related to erythropoiesis-stimulating agents (ESA's), Ortho Biotech reiterates its position on the following key issues that will be discussed:

* The studies being examined by the FDA Advisory Committees evaluated hemoglobin targets above 13 grams per deciliter of blood (g/dL).

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement